


Daniel Ortiz, Clerk
Acting Clerk of Court Office
Daniel Patrick Moynihan, U.S. Courthouse
United States District Court
Southern District of New York
500 Pearl Street, Room 120
New York, New York 10007



June 9, 2025,

Re: Lead Case No. 7:21-cv-7532(CM) and 7:21-cv-08049(CM)


Dear Mr. Ortiz, Clerk

Find copy of my letter to Judge Sean H. Lean, U.S.B.J. I am not voting for the restructuring of Purdue Pharma LP, et al., or the release of the Shackler family, et al., consistent with the Supreme Court decision in *Harrington v. Purdue Pharma, LP, et al.*, under the merit of the case 11 U.S.C, § 1123(b)(6), see U.S. District Court Southern District of New York, Case No. 1:23-cv-4340 (Third Parties-non-debtors) liabilities.

Ronald Bass, Sr.

cc: Hon. Colleen McMahon, U.S.D.J.
Hon. Laura Taylor Swain, U.S.D.J.
Hon. Sean H. Lean, U.S.B.J.
Attorney for Purdue Pharma, et al.,
Attorney for the Creditors

Ronald Bass, Sr.
450 Little Place, Apt. 53
N. Plainfield, New Jersey 07060
(908) 374-9321
Email: Ronaldbass12345@gmail.com



Hon. Sean H. Lane, U.S.B.J.
United States Bankruptcy Court
Southern District of New York
300 Quarropas Street
White Plains, New York 10601-4140

Chapter 11
Case No. 19-23649 (SHL)

(Jointly Administered)

**Re: In re PURDUE PHARMA L.P., et. al.,
Debtors**

Dear Judge Lane

I am not voting for the restructuring of the Purdue Pharma, LP, et al., plan under Chapter 11 and the ongoing hiring of professional services of public or private entities paid with extravagant fees for redundant discussion at the mediation hearings, which hasn't held the **Sacklers Family, et al.**, liable for personal injuries damages in my claims and, fraudulent conveyances, see 11 U.S.C. § 548 with Partners Pharmacy, LLC opioid distributors and the **unjust enrichments of the State of New Jersey, et al 'Opioid Settlement'**; The Mediations has not complied with the order and judgment of the Supreme Court of the United States, decision in *Harrington v. Purdue Pharma, L.P., et al.*, § 1123(b)(6); I am being denied constitutional **due process, 5th and 14th Amend.**

"What functioning the court has been performing is smothered and surmised," in my **core** and **non-core** claims"; I, have not sited down with the Sacklers family, et al., or the State of New Jersey, et al., or any of the private or public person and entities that listed in my pharmaceutical records or insurance coverage under New Jersey Department of Human Services, et al., see New Jersey 1947 Constitution, of **due process of life and liberty.**

cc: United State District Court, Clerk Office
Pro se, Unit.

Courtesy copy to Judge's Chambers

Davis Polk & Wardell, LLP (Mr. Huebner)

Attachments

A handwritten signature in black ink, reading "Ronald Bass". The signature is written in a cursive style with a large, stylized "B" and a long, sweeping underline.

Accession #: 14304243480

Lab: LabCorp

Patient: Bass, Ronald

Pat. Chart No.: PT00008736

DOB: 03/19/1955

Age: 59 Yr(s) 2 Month(s)

Gender: Male

Client Info.: 29708390

Gastromed Healthcare, P.A. Bridgew.

(908) 231-1999

25 Monroe Street

Bridgewater, NJ 08807

Ordering Physician: Unger, Jeffrey

Lab Order No.: 4783

Print Date: 05/23/2014

Report Status: Final

Collected: 05/23/2014 00:00

Received: 05/24/2014 03:19

Reported: 05/26/2014 08:09

Test Name	Flag	Result Value (Unit)	Reference Range	Lab
Occult Blood, Fecal, Ia				
Occult Blood, Fecal, Ia		Negative	Negative	01

Performing Laboratory Information:

01 LabCorp Raritan 69 First Avenue Raritan NJ 088691800. MD Reyes Araceli B MD 8006315250

GASTROMED HEALTHCARE, P.A.*Jeffrey S. Unger, M.D.*

Board Certified in Gastroenterology

25 Monroe St., Bridgewater, NJ 08807 908-231-1999

203 Towne Centre Dr., Hillsborough, NJ 08844 908-359-1639

ASSOCIATED WITH:

Robert S. Wiesen, M.D.**Surya P. Irakam, M.D., FACP, FACG**Website: www.gastromedhealthcare.com

Bass, RonaldDOB: **03/19/1955****Patient Report**Patient ID: **661634**Age: **66**Account Number: **29729685**Specimen ID: **120-425-1467-0**Sex: **Male**Ordering Physician: **B Bilal**Date Collected: **04/30/2021**Date Received: **04/30/2021**Date Reported: **05/01/2021**Fasting: **Not Given**Ordered Items: **H. pylori Stool Ag, EIA****General Comments & Additional Information**

Clinical Info: SRC: STOOL

Date Collected: **04/30/2021****H. pylori Stool Ag, EIA**

Test	Current Result and Flag	Units	Reference Interval
H. pylori Stool Ag, EIA ⁰¹	Negative		Negative

Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend

▲ Out of Reference Range ■ Critical or Alert

Performing Labs

01: RN - LabCorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Araceli B Reyes, MD

For Inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250

Patient Details**Bass, Ronald**

**450 Little Place Apt. 53, N Plainfield, NJ,
07060**

Phone: **908-374-9321**Date of Birth: **03/19/1955**Age: **66**Sex: **Male**Patient ID: **661634**Alternate Patient ID: **661634****Physician Details****B Bilal****Medemerge**

**1005 N Washington Ave, Green Brook, NJ,
08812**

Phone: **732-968-8900**Account Number: **29729685**

Physician ID:

NPI: **1518368257****Specimen Details**Specimen ID: **120-425-1467-0**Control ID: **1858854**Alternate Control Number: **1858854**Date Collected: **04/30/2021 1356 Local**Date Received: **04/30/2021 0000 ET**Date Entered: **04/30/2021 2357 ET**Date Reported: **05/01/2021 2205 ET**

United States Patent [19]
Gallo et al.

[11] **Patent Number:** **4,647,773**
 [45] **Date of Patent:** * **Mar. 3, 1987**

[54] **METHOD OF CONTINUOUS PRODUCTION
 OF RETROVIRUSES (HTLV-III) FROM
 PATIENTS WITH AIDS AND PRE-AIDS**

[75] **Inventors:** Robert C. Gallo; Mikulas Popovic,
 both of Bethesda, Md.

[73] **Assignee:** The United States of America as
 represented by the Department of
 Health and Human Services,
 Washington, D.C.

[*] **Notice:** The portion of the term of this patent
 subsequent to May 28, 2002 has been
 disclaimed.

[21] **Appl. No.:** 602,946

[22] **Filed:** Apr. 23, 1984

[51] **Int. Cl.⁴** C12N 7/02; C12N 7/00;
 C12N 5/00; C12R 1/91

[52] **U.S. Cl.** 435/239; 435/235;
 435/240; 435/948; 424/89

[58] **Field of Search** 435/235, 239, 240, 948,
 435/5, 29; 424/89; 128/1 T

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,464,465 8/1984 Lofstrom et al. 435/948
 4,520,113 5/1985 Gallo et al. 435/7

OTHER PUBLICATIONS

Popovic et al, *Science*, 224(4648):497-500, May 4, 1984.
 Gallo et al, "Isolation of Human T-Cell Leukemia
 Virus in Acquired Immune Deficiency Syndrome
 (AIDS)", *Science*, 220, pp. 865-867 (5-1983).
 Barra-Sinoussi et al, "Isolation of a T-Lymphotropic
 Retrovirus from a Patient at Risk for AIDS", *Science*,
 220, pp. 868-871 (5-1983).
 Marx, "Strong New Candidate for AIDS Agent", *Sci-*
ence, 224, pp. 475-477 (5-1984).

Primary Examiner—Charles F. Warren
Assistant Examiner—John Edward Tarcza
Attorney, Agent, or Firm—John S. Roberts, Jr.

[57] **ABSTRACT**

A cell system is disclosed for the reproducible detection
 and isolation of human T-lymphotropic retroviruses
 (HTLV-family) with cytopathic effects (HTLV-III)
 from patients with the acquired immune deficiency
 syndrome (AIDS), pre-AIDS and in healthy carriers.
 One neoplastic aneuploid T-cell line derived from an
 adult with lymphoid leukemia, and termed HT,
 was susceptible to infection with the new variants of HTLV,
 which are transformed and providing T-cell popula-
 tions which are highly susceptible and permissive from
 HTLV-III, and convenience for large scale production,
 isolation and biological detection of the virus.

15 Claims, No Drawings

4,647,773

1

METHOD OF CONTINUOUS PRODUCTION OF RETROVIRUSES (HTLV-III) FROM PATIENTS WITH AIDS AND PRE-AIDS

The present invention describes a cell system for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic or cell killing effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with the new variants of HTLV, providing T-cell populations which are highly susceptible and permissive for HTLV-III, and convenience for large scale production, isolation, and biological detection of the virus.

BACKGROUND OF THE INVENTION

The disclosure of this invention is contained in the following journal articles: Gallo et al., "Detection, Isolation, and Continuous Production of Cytopathic Human T-Lymphotropic Retroviruses (HTLV-III) from Patients with AIDS and pre-AIDS," *Science*, in press; and Gallo et al., "Human T-Lymphotropic Retrovirus, HTLV-III, Isolated from AIDS Patients and Donors at Risk for AIDS," in press.

Epidemiologic data strongly suggest that acquired immune deficiency syndrome (AIDS) is caused by an infectious agent which is apparently horizontally transmitted by intimate contact or blood products. Though the disease is manifested by opportunistic infections, predominantly *Pneumocystis carinii* pneumonia and Kaposi's sarcoma, the underlying disorder affects the patient's cell-mediated immunity with absolute lymphopenia and reduced helper T-lymphocyte (OKT4+) subpopulation(s). Moreover, before a complete clinical manifestation of the disease occurs, its prodrome, pre-AIDS, is frequently characterized by unexplained chronic lymphadenopathy and/or leukopenia involving a helper T cell subset. This leads to the severe immune deficiency of the patient, suggesting that a specific subset of T-cells is the primary target for an infectious agent. Although patients with AIDS or pre-AIDS are often chronically infected with cytomegalovirus or hepatitis B virus, for various reasons these appear to be opportunistic or coincidental infections apparently not linked to the immunological response deficiency. It is believed that the cause of AIDS may be a virus from the family of human T-cell lymphotropic retroviruses (HTLV) which, prior to the present invention, comprised two major well characterized subgroups of human retroviruses, called human T-cell leukemia/lymphoma viruses, HTLV-I and HTLV-II. The most common isolate, HTLV-I, is mainly obtained from patients with mature T-cell malignancies. Seroepidemiological studies, in vitro biological effects, and nucleic acid hybridization data indicate that HTLV-I is etiologically associated with these malignancies, affecting adults primarily in the south of Japan, the Caribbean and Africa. HTLV of subgroup II (HTLV-II) was first isolated from a patient with a T-cell variant of hairy cell leukemia. To date, this is the only reported isolate of HTLV-II from a patient with a neoplastic disease. Virus isolation and seroepidemiological data show that HTLV of both subgroups can sometimes be found in patients with AIDS.

2

Evidence suggests that the retrovirus(es) of the HTLV family is an etiological agent of AIDS based on the following: (1) there is precedence for an animal retrovirus cause of immune deficiency (feline leukemia virus in cats); (2) retroviruses of the HTLV family are T-cell tropic; (3) they preferentially infect "helper" T-cells (OKT4+); (4) they have cytopathic effects on various human and mammalian cells as demonstrated by their induction of cell syncytia formation; (5) they can alter some T-cell functions; (6) in some cases infection may result in selective T-cell killing; and (7) they are transmitted by intimate contact or through blood products. The presence of antibodies directed to cell membrane antigens of HTLV infected cells has been shown in sera of more than 40% of patients with AIDS [Essex et al., *Science*, 220:859 (1983)]. This antigen has since been defined as part of the envelope of HTLV [Schüpbach, et al., *Science*, in press; and Lee, et al., *Proc. Nat. Acad. Sci. U.S.A.*, in press].

The original detection and isolation of the various HTLV isolates were made possible by two earlier developments: the discovery of T-cell growth factor (TCGF), also called Interleukin 2 (IL-2), which enabled the routine selective growth of different subsets of normal and neoplastic mature T-cells [Ruscetti, et al., *J. Immunol.*, 119:131 (1977); and Poiesz, et al., *Proc. Nat. Acad. Sci. U.S.A.*, 77:6134 (1980)] and the development of sensitive assays for detection of retroviruses based on reverse transcriptase assays. The methods of HTLV isolation and transmission involved a cocultivation procedure using permissive T-cells for the virus. The use of normal human T-cells in cocultivation experiments preferentially yielded HTLV of both subgroups with immortalizing (transforming) capability for some of the target T-cells.

However, HTLV variants (now termed HTLV-III), lack immortalizing properties for normal T-cells and mainly exhibit cytopathic effects on the T-cells and is now believed to be the cause of AIDS. In fact, such variants were frequently but only transiently detected using these normal T-cells as targets in cocultivation or cell-free transmission experiments. The cytopathic effect was overcome by finding a highly susceptible, permissive cell for cytopathic variants of HTLV, thus preserving the capacity for permanent growth after infection with the virus. The present invention discloses the identification and characterization of this new immortalized T-cell population and its use in the isolation and continuous high-level production of such viruses from patients with AIDS and pre-AIDS.

Early experiments identified one neoplastic aneuploid T-cell line, termed HT, derived from an adult with lymphoid leukemia, that was susceptible to infection with the new cytopathic virus isolates.

This cell line is a sensitive target for transmission of these virus isolates (HTLV-III) and it allows continuous large-scale virus production and development of specific immunologic reagents and nucleic acid probes useful for comparison of these new isolates among themselves and with HTLV-I and HTLV-II. In addition to their differences in biological effects that distinguish them from HTLV-I and HTLV-II, HTLV-III also differs from these known HTLV subgroups in several immunological assays and in morphology. However, these new retroviruses are T4 lymphotropic and exhibit many properties similar to HTLV-I and II, including similar properties of the reverse transcriptase, cross reactivity of structural proteins as determined by

3

heterologous competition radioimmune assays with patients' sera and with animal hyperimmune sera, and induction of syncytia. These new retrovirus isolates are collectively designated HTLV-III, together with detectable differences in some of their proteins and genetic information, HTLV-III's ability to kill T-cells clearly separates these variants from other members of the HTLV family.

STATEMENT OF DEPOSIT

A cell line corresponding to the present invention, and denoted H9/HTLV-III_B, has been deposited in the ATCC (under ATCC No. CRL 8543) on Apr. 19, 1984, prior to the filing of this patent application. This deposit assures permanence of the deposit and ready accessibility thereto by the public. H9 is a representative and preferred cell line in accordance with the invention.

UTILITY STATEMENT

The cell line which is a product of the present invention (H9/HTLV-III_B) is presently useful for the production of vaccines for the relief of AIDS and for the detection of antibodies to the virus in blood samples.

GENERAL DESCRIPTION

A susceptible cell line HT was tested for HTLV before in vitro infection and it was negative by all criteria, including lack of proviral sequences. Continuous production of HTLV-III is obtained after repeated exposure of parental HT cells (3×10^6 cells pretreated with polybrene) to concentrated culture fluids containing HTLV-III harvested from short term cultured T-cells (grown with TCGF) which originated from patients with pre-AIDS or AIDS. The concentrated fluids were first shown to contain particle associated reverse transcriptase (RT). When cell proliferation declined, usually 10 to 20 days after exposure to the culture fluids, the fresh (uninfected) HT parental cells are added to cultures. Culture fluids from the infected parental cell line was positive for particulate RT activity and about 20% of the infected cell population was positive in an indirect immune fluorescent assay (IFA) using serum from a hemophilia patient with pre-AIDS (patient E.T.). Serum from E.T. also contained antibodies to proteins of disrupted HTLV-III but did not react with proteins of HTLV-I or HTLV-II infected cells.

SPECIFIC DISCLOSURE

As has been mentioned above, an aneuploid HT-cell line exhibited the desired prerequisites for the continuous propagation of HTLV-III. This cell line is a neoplastic aneuploid T-cell line derived from an adult patient with lymphoid leukemia, selected for its mature T-cell phenotype [OKT3+ (62%), OKT4+ (39%) and OKT8-], as determined by cytofluorometry using a fluorescence-activated cell sorter. Cultures of these cells are routinely maintained in RPMI/1640 with 20% fetal calf serum and antibiotics. These cultures are shown in Example 1, Table 1. Clone H9 is preferred, with Clone H4 being secondarily preferred.

HTLV-III culture fluids are isolated from cultured cells of patients with acquired immune deficiency syndrome (AIDS). Peripheral blood leukocytes from these patients are banded in Ficoll-Hypaque, incubated in growth media (RPMI 1640, 20% fetal bovine serum 0.29 mg/ml glutamine) containing 5 μ g/ml phytohemagglutinin (PHA-P) for 48 hours, at 37° C. in a 5% CO₂ atmosphere. The leukocytes are then refed with growth

4,647,773

4

medium containing 10% purified T cell growth factor (TCGF); optionally, some of the cells also received rabbit antibody to alpha interferon. Cells and growth media from these lymphocytes are then assayed for the presence of HTLV subgroups I-III. Samples exhibiting more than one of the following were considered positive: repeated detection of a Mg⁺⁺ dependent reverse transcriptase activity in supernatant fluids; virus observed by electron microscopy; intracellular expression of virus-related antigens detected with antibodies from sero-positive donors or with hyperimmune serum; or transmission of particles, detected by reverse transcriptase assays or by electron microscopic observation, to fresh human cord blood, bone marrow, or peripheral blood T-lymphocytes. All isolates not classified as either HTLV-I or HTLV-II by immunological or nucleic acid analysis were classified as HTLV-III. The cells in the HTLV-III producing cell cultures, characterized using established immunological procedures, are predominantly T-lymphocytes (E rosette receptor, OKT/3 and Leu/1 positive, with a T4 phenotype (OKT4, leu 3a positive). This process is also described by Gallo, et al., in *Science*, 220:865-867 (1983).

The infection of parental HT cells as well as other cloned cell populations occurs by exposure of these cells to concentrated or nonconcentrated culture fluids (cell-free infection) from T-cell cultures from AIDS or pre-AIDS patients, or by cocultivation; that is, HT cells are infected by exposure to HTLV-III containing cultures. The usual cell-free infection procedure is as follows: 2 to 5×10^6 cells are treated with polybrene (2 μ g/ml) or DEAE dextran for 30 minutes in CO₂ incubator at 37° C., and then exposed to the virus inoculum (0.1 to 1 ml) for one hour in the incubator (CO₂/37° C.). The cells are kept in suspension by shaking at regular intervals. After one hour of incubation a regular growth medium is added. The positivity of infected cultures for HTLV-III is assessed after one, two, and three weeks of cultivation.

The infection of HT cells (clones) is also obtained by cocultivation procedure—HT cells are mixed in various proportions (usually 1:5) with short-term cultured T-cells (about 5 to 20 days) from AIDS or pre-AIDS patients. The positivity for HTLV-III was scored by the detection of viral antigens or viral nucleic acid sequences in the infected recipient cells at various intervals (7, 14, 21 days, etc.) after cocultivation. The mixed cultures are maintained in growth medium for several months.

EXAMPLE 1

As shown in Table 1 below, single cell HT clones were isolated as described by Popovic, et al., in *Neoplasia*, 18:257 (1971), and Bach, et al., *Immunol. Rev.*, 54:5 (1981) from a long-term cultured aneuploid HT-cell line exhibiting mature T-cell phenotype (OKT3+ [62%], OKT4+ [39%] and OKT8-) as determined by cytofluorometry using a fluorescence-activated cell sorter. The cultures were routinely maintained in RPMI/1640 with 20% fetal calf serum and antibiotics. The terminal cell density of the parental cell culture, seeded at a concentration of 2×10^5 cells/milliliter of culture media, was in the range 10^6 - 1.5×10^6 cells/ml after 5 days of culture.

For detection of multinucleated cells, cell smears were prepared from cultures 6 and 14 days after infection and stained with Wright-Giemsa. Cells having more than 5 nuclei were considered as multi-nucleated

4,647,773

5

cells. Cloned cells from uninfected cultures also contained some multi-nucleated giant cells as well; however, the arrangement of multiple nuclei in a characteristic ring formation was lacking and the number of these

6

Triton X-100/1.5M KCl. Reverse transcriptase (RT) assays were performed as described by Poiesz, et al., *Proc Nat. Acad. Sci. U.S.A.*, 77:7415 (1980) and expressed in cpm per milliliter culture medium.

TABLE 1

Characteristics	Response of Cloned T-Cell Populations to HTLV-III Infection							
	Clones							
	H3	H4	H6	H9	H17	H31	H35	H38
<u>Total cell number ($\times 10^6$)</u>								
6 days after infection	1	1.5	1.5	0.3	0.4	0.3	0.5	1.8
14 days after infection	2.2	7.3	7.5	10.0	4.7	5.0	4.5	3.2
<u>Multinucleated cells (%)</u>								
6 days after infection	24	42	32	7	13	14	30	45
14 days after infection	45	48	45	30	22	45	60	60
<u>Immunofluorescence positive cells (%)</u>								
6 days after infection								
Rabbit antiserum to HTLV-III	55	56	32	32	39	21	10	87
Patient serum (E.T.)	56	29	21	ND	ND	ND	ND	73
14 days after infection								
Rabbit antiserum to HTLV-III	50	74	60	97	71	40	20	80
Patient serum	45	47	56	78	61	43	22	89
<u>Reverse transcriptase activity ($\times 10^4$ cpm/ml)</u>								
6 days after infection	2.4	1.8	2.1	4.1	2.6	1.4	1.7	2.5
14 days after infection	16.2	18.1	16.1	20.2	17.1	13.4	15.1	18.2

ND = not done

cells was much less (0.7% to 10%).

Immunofluorescence positive cells were washed with phosphate-buffered saline (PBS) and resuspended in the same buffer at concentration 10^6 cells per milliliter. Approximately 50 λ of cell suspension were spotted on slides, air dried, and fixed in acetone for 10 min. at room temperature. Slides were stored at -20° C. until use. Twenty microliters of either hyperimmune rabbit antiserum to HTLV-III (diluted 1/2000 in PBS) or serum from the patient (E.T.) diluted 1/8 in PBS was applied to cells and incubated for 50 min. at 37° C. The fluorescein-conjugated antiserum to rabbit or human immunoglobulin G was diluted and applied to the fixed cells for 30 min. at room temperature. Slides then were washed extensively before microscopic examinations. The uninfected parental cell line as well as the clones were consistently negative in these assays.

To determine reverse transcriptase activity, virus particles were precipitated from cell-free supernatant as follows: 0.4 ml of 4M NaCl and 3.6 ml of 30% (wt/vol.) polyethylene glycol (Carbowax 6000) were added to 8 ml of harvested culture fluids and the suspension was placed on ice overnight. The suspension was centrifuged in a Sorvall RC-3 centrifuge at 2000 rpm at 4° C. for 30 min. The precipitate was resuspended in 300 μ l at 50% (vol/vol) glycerol (25 mM Tris-HCl, pH 7.5/5mM dithiothreitol/150 mM KCl/0.025% Triton X-100. Particles were disrupted by addition of 100 μ l of 0.9%

EXAMPLE 2

As shown in Table 2 below, cocultivation with H4 recipient T-cell clone was performed with fresh mononuclear cells from peripheral blood of patients RF and SN, respectively. In the case of patients BK and LS cocultivation was performed with T-cells grown in the presence of exogenous TCGF (10% V/V) for 10 days. The ratio recipient/donor (patients') cells was 1:5. The mixed cultures were maintained in RPMI/1640 (20% FCS and antibiotics) in the absence of exogenous TCGF. Cell free infection of H9 T-cell clone was performed using concentrated culture fluids harvested from T-cell cultures of the patient WT. The T-cell cultures were grown in the presence of exogenous TCGF for two weeks before the culture fluids were harvested and concentrated. Cells of H9 clones were pretreated with polybrene (2 μ g/ml) for 20 min. and 2×10^6 cells were exposed for one hr. to 0.5 ml of 100-fold concentrated culture fluids positive for particulate RT activity.

HTLV-III virus expression in both cocultured and cell-free infected cell cultures were assayed approximately one month after in vitro cultivation. There was considerable fluctuation in HTLV-III expression (see Table 2). For details of both reverse transcriptase (RT) assays and indirect immunofluorescence assays (IFA) see Example 1.

TABLE 2

Isolation of HTLV-III from Patients with Pre-AIDS and AIDS						
Patient	Diagnosis	Origin	RT Activity ($\times 10$ cpm)	Virus Expression		EM
				Rabbit Serum (% Positive)	IFA with	
					Human Serum (ET) (% Positive)	
RF	AIDS (heterosexual)	Haiti	0.25	80	33	ND
SN	Hemophilic (lymphadenopathy)	U.S.	6.3	10	ND	+
BK	AIDS (homosexual)	U.S.	0.24	44	5	+
LS	AIDS (homosexual)	U.S.	0.13	64	19	+

TABLE 2-continued

Isolation of HTLV-III from Patients with Pre-AIDS and AIDS						
Patient	Diagnosis	Origin	RT Activity ($\times 10$ cpm)	Virus Expression		EM
				IFA with		
				Rabbit Serum (% Positive)	Human Serum (ET) (% Positive)	
WT	Hemophilic (lymphadenopathy)	U.S.	3.2	69	ND	ND

RT = reverse transcriptase
IFA = immunofluorescence assays
EM = electron microscopy
ND = not done

EXAMPLE 3

To select for high permissiveness for HTLV-III and to preserve permanent growth and continuous production of virus, extensive cloning of the HT parental T-cell population was performed. A total of 51 single-cell clones was obtained by both capillary and limited dilution techniques using irradiated mononuclear cells from peripheral blood of a healthy donor as a feeder. The growth of these cell clones was compared after HTLV-III infection. A representative example of response to virus infection of 8 T-cell clones which are susceptible to and permissive for HTLV-III is shown in Table 1. In parallel experiments, 2×10^6 cells of each T-cell clone were exposed to 0.1 ml of concentrated virus. Then cell growth and morphology, expression of cellular viral antigen(s), and RT activity in culture fluids were assessed 6 and 14 days after infection. Although all 8 clones were susceptible to and permissive for the virus, there were considerable differences in their ability to proliferate after infection. The cell number decreased by 10% to 90% from the initial cell count within 6 days after infection, and a high proportion of multinucleated (giant) cells were consistently found in all 8 infected clones. The percentage of T-cells positive for viral antigen(s) determined by immunofluorescent assays with serum from AIDS patient (E.T.) and with hyperimmune rabbit serum raised against the whole disrupted HTLV-III ranged from 10% to over 80%. Fourteen days after infection, the total cell number and the proportion of HTLV-III positive cells increased in all 8 clones. The virus positive cultures consistently showed round giant cells which contained numerous nuclei. These multinucleated giant cells are similar to those induced by HTLV-I and HTLV-II except that the nuclei exhibit a characteristic ring formation. Electron microscopic examinations showed that the cells released considerable amounts of virus.

EXAMPLE 4

To determine whether HTLV-III is continuously produced by the infected T-cells in long-term cultures, both virus production and cell viability of the infected clone, H4, were followed for several months. Although the virus production fluctuated, culture fluids harvested from the H4/HTLV-III cell cultures at approximately 14-day intervals consistently exhibited particulate RT activity which has been followed for over 5 months. The viability of the cells ranged from 65% to 85% and doubling time of the cell population, which is called H4/HTLV-III, was approximately 30-40 hours. Thus, this permanently growing T-cell population can continuously produce HTLV-III.

The yield of virus produced by H4/HTLV-III cells was assessed by purification of concentrated culture fluids through a sucrose density gradient and assays of particulate RT activity in each fraction collected from

the gradient. The highest RT activity was found at density 1.16 g/ml, similar to other retroviruses.

We claim:

1. A method for continuous production of HTLV-III virus which comprises infecting in cell culture highly susceptible, permissive cells consisting of a neoplastic aneuploid HT-cell line with said virus, said cells preserve the capacity for permanent growth after the infection with said virus, growing said cells under conditions suitable for cell growth and recovering said virus produced by said cells.

2. The method of claim 1, wherein said virus consists of cytopathic variants of HTLV.

3. The method of claim 1 wherein said infecting comprises cocultivating said virus with said cells to produce a cell line and recovering said cell line.

4. The method of claim 1 wherein said infecting comprises cell-free infection of said cells with said virus.

5. The method of claim 1 wherein said cells are neoplastic aneuploid T-cells derived from an adult with lymphoid leukemia.

6. A process for the continuous production of HTLV-III virus which comprises cocultivating said virus with a target HT-cell to produce an infected cell line, growing said cell line and recovering said virus from supernatants produced by said cell line.

7. The process of claim 6 wherein said target T-cell is a neoplastic aneuploid T-cell susceptible to infection with HTLV-III.

8. A process for the continual production of HTLV-III by infecting T-cells in cultures which comprises cocultivating HTLV-III virus with an HT-clone to produce an infected cell line, said clone being an aneuploid T-cell line derived from lymphoid leukemia, growing said cell line and recovering said virus from supernatants produced by said cell line.

9. The process in claim 8 wherein said clone is a mature T-cell phenotype of OKT3+ (62%), OKT4+ (39%) and OKT8-.

10. A method of producing a cell line containing an antigen of HTLV-III which comprises infecting an HT-cell line derived from lymphoid leukemia and susceptible to infection with HTLV-III, said cell line is capable of continuous large-scale production of HTLV-III, and growing the infected cell line under conditions suitable for growth.

11. The method of claim 10 wherein said cell line is a neoplastic aneuploid T-cell line.

12. The method of claim 10 wherein said HTLV-III are variants of human T-lymphotropic retrovirus, exhibit cytopathic effects and are non-transforming.

13. A cell line containing HTLV-III designated H9/HTLV-III_B, ATCC Accession CRL 8543.

14. A process for producing a cell line H9/HTLV-III_B which comprises infecting a target T-cell with

4,647,773

9

HTLV-III virus to produce a cell line and recovering same, said infecting process overcomes the normal cytopathic effect of HTLV-III and preserves the immortal growth capacity of the target cell.

15. An HT cell line permanently infected with 5

10

HTLV-III virus, wherein said cell line continually produces said virus.

* * * * *

10

15

20

25

30

35

40

45

50

55

60

65

Ronald Bass, Sr.
450 Little Place, Apt. 53
W. Plainfield NJ 07060



AMS
SDNY

Don Sean H. Lane, U.S.B.A.
United States Bankruptcy Court
Southern District of New York
300 Quarropas Street
White Plains, NY 10601

